Last reviewed · How we verify
Capozide 25/15 (CAPTOPRIL)
Capozide 25/15 (Captopril) is a small molecule Angiotensin Converting Enzyme Inhibitor (ACE inhibitor) developed by PAR PHARM and currently owned by Aarxion Anda Hlding. It targets the renin system to treat chronic heart failure, diabetic renal disease, hypertensive disorder, and left ventricular cardiac dysfunction. Capozide 25/15 was FDA approved in 1981 and is now off-patent with 21 generic manufacturers. It has a half-life of 2.0 hours and bioavailability of 69%. Key safety considerations include monitoring of renal function and potassium levels.
At a glance
| Generic name | CAPTOPRIL |
|---|---|
| Sponsor | Aarxion Anda Hlding |
| Drug class | Thiazide Diuretic [EPC] |
| Target | Renin |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
- Chronic heart failure
- Diabetic renal disease
- Hypertensive disorder
- Left ventricular cardiac dysfunction
Boxed warnings
- BOXED WARNING USE IN PREGNANCY When used in pregnancy during the second and third trimesters, ACE Inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, captopril and hydrochlorothiazide should be discontinued as soon as possible. See WARNINGS: Captopril: Fetal/Neonatal Morbidity and Mortality .
Common side effects
- Renal Insufficiency
- Renal Failure
- Nephrotic Syndrome
- Polyuria
- Oliguria
- Urinary Frequency
- Neutropenia/Agranulocytosis
- Anemia
- Thrombocytopenia
- Pancytopenia
- Pruritus
- Rash
Drug interactions
- indomethacin
- lithium
- spironolactone
- triamterene
Key clinical trials
- The Use of Virtual Reality and Music Therapy for Hypertensive Urgency (NA)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Comparative Efficacy of ARNI Versus ACE Inhibitor Therapy in Egyptian Children With Dilated Cardiomyopathy
- A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril (PHASE1)
- Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease (EARLY_PHASE1)
- Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans
- Cardioprotection on Chemotherapy-Induced Cardiotoxicity (PHASE3)
- New Horizons for the Treatment of Cardiomyopathy in Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |